A previous study scoured cancer genomic databases and found that CFP1 has high mutation rates in colon adenocarcinoma, endometrial carcinoma, and prostate cancers, and even a significant co-occurrence of genetic aberration.9 However, studies on the role of CFP1 in LUAD are insufficient. The gene discussed is CXXC1; the disease is prostate carcinoma.